Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
IRD Opus Genetics	$1.11 +4.7%	$0.99	$0.65 ▼ $1.75	$63.24M	-0.02	517,582 shs	557,410 shs
OSTX OS Therapies	$1.66 +2.5%	$1.78	$1.12 ▼ $7.00	$46.64M	N/A	489,952 shs	419,114 shs
PMCB Nuvilex	$1.11 +0.9%	$1.07	$1.00 ▼ $2.42	$7.55M	-0.42	19,702 shs	7,872 shs
RVPH Reviva Pharmaceuticals	$0.39 +3.5%	$0.75	$0.30 ▼ $4.28	$18.08M	-0.06	1.37 million shs	3.19 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
IRD Opus Genetics	+4.72%	+12.12%	+5.71%	+55.51%	+110,999,900.00%
OSTX OS Therapies	+2.47%	-13.09%	-16.16%	+48.21%	+165,999,900.00%
PMCB Nuvilex	+0.91%	-1.77%	+6.73%	-2.63%	-45.32%
RVPH Reviva Pharmaceuticals	+3.53%	+1.27%	-53.86%	-32.74%	-67.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
IRD Opus Genetics	1.4919 of 5 stars	3.5	0.0	1.2	0.0	0.6
OSTX OS Therapies	2.7831 of 5 stars	3.7	0.0	2.9	1.7	0.6
PMCB Nuvilex	0.8956 of 5 stars	0.0	3.0	0.6	0.8	1.9
RVPH Reviva Pharmaceuticals	2.2723 of 5 stars	3.6	1.0	0.6	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
IRD Opus Genetics	3.00	Buy	$7.33	560.66% Upside
OSTX OS Therapies	3.40	Buy	$18.00	984.34% Upside
PMCB Nuvilex	0.00	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	3.29	Buy	$9.00	2,208.28% Upside

Current Analyst Ratings Breakdown

Latest PMCB, RVPH, OSTX, and IRD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/27/2025	IRD Opus Genetics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00
6/27/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
6/24/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/9/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00
6/3/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
5/20/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $3.00
5/15/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/24/2025	RVPH Reviva Pharmaceuticals	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
4/22/2025	OSTX OS Therapies	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
4/11/2025	IRD Opus Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00

(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
IRD Opus Genetics	$10.99M	6.03	N/A	N/A	$0.21 per share	5.29
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A	N/A
PMCB Nuvilex	N/A	N/A	N/A	N/A	$3.27 per share	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	$0.02 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
IRD Opus Genetics	-$57.53M	-$2.10	N/A	N/A	N/A	-429.42%	-283.28%	-144.32%	8/12/2025 (Estimated)
OSTX OS Therapies	-$7.79M	-$0.86	N/A	N/A	N/A	N/A	N/A	-569.57%	N/A
PMCB Nuvilex	$330K	$0.74	1.50	∞	N/A	N/A	0.51%	0.35%	8/11/2025 (Estimated)
RVPH Reviva Pharmaceuticals	-$29.92M	-$0.79	N/A	N/A	N/A	N/A	N/A	-302.31%	8/13/2025 (Estimated)

Latest PMCB, RVPH, OSTX, and IRD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/15/2025	Q1 2025	IRD Opus Genetics	-$0.34	-$0.32	+$0.02	-$0.24	$4.00 million	$4.30 million
5/15/2025	Q1 2025	RVPH Reviva Pharmaceuticals	-$0.21	-$0.13	+$0.08	-$0.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
IRD Opus Genetics	N/A	N/A	N/A	N/A	N/A
OSTX OS Therapies	N/A	N/A	N/A	N/A	N/A
PMCB Nuvilex	N/A	N/A	N/A	N/A	N/A
RVPH Reviva Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
IRD Opus Genetics	N/A	1.98	1.98
OSTX OS Therapies	N/A	0.76	0.76
PMCB Nuvilex	N/A	14.21	14.21
RVPH Reviva Pharmaceuticals	N/A	0.54	0.54

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
IRD Opus Genetics	14.97%
OSTX OS Therapies	N/A
PMCB Nuvilex	34.24%
RVPH Reviva Pharmaceuticals	63.18%

Insider Ownership

Company	Insider Ownership
IRD Opus Genetics	6.60%
OSTX OS Therapies	13.80%
PMCB Nuvilex	10.20%
RVPH Reviva Pharmaceuticals	27.18%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
IRD Opus Genetics	14	59.66 million	55.72 million	N/A
OSTX OS Therapies	N/A	28.10 million	N/A	N/A
PMCB Nuvilex	4	6.86 million	6.16 million	Optionable
RVPH Reviva Pharmaceuticals	5	48.00 million	34.96 million	Optionable

PMCB, RVPH, OSTX, and IRD Headlines

Recent News About These Companies

Reviva Pharmaceuticals Holdings, Inc. (RVPHW) - Yahoo Finance

July 5, 2025 | finance.yahoo.com

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Recommendation of "Buy" by Analysts

July 5, 2025 | americanbankingnews.com

Reviva Pharmaceuticals Holdings, Inc. (RVPH) - Investing.com

June 29, 2025 | investing.com

Reviva Dives on Stock Offering

June 26, 2025 | baystreet.ca

Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering

June 26, 2025 | globenewswire.com

Reviva Pharmaceuticals stock falls after announcing public offering

June 25, 2025 | za.investing.com

Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering

June 25, 2025 | globenewswire.com

RVPH: Open Label Extension Results & Key Opinion Leader Discussion

June 5, 2025 | finance.yahoo.com

Reviva to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 5, 2025 | globenewswire.com

Reviva Announces Positive Full Dataset for 1-Year Phase 3 RECOVER Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

June 2, 2025 | globenewswire.com

Reviva to Participate in Upcoming Investor Conferences in May 2025

May 20, 2025 | santelog.comS

Reviva Reports First Quarter 2025 Financial Results and Recent Business Highlights

May 15, 2025 | globenewswire.com

Reviva to Participate in the A.G.P. Healthcare Company Showcase

May 13, 2025 | finance.yahoo.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Icon (ICLR), Reviva Pharmaceuticals Holdings (RVPH) and SurModics (SRDX)

May 4, 2025 | theglobeandmail.com

Reviva to Participate in the Citizens Life Sciences Conference

April 29, 2025 | finance.yahoo.com

RVPH: M&A Deals Highlight Brilaroxazine Value

April 7, 2025 | finance.yahoo.com

Roth MKM Reaffirms Their Buy Rating on Reviva Pharmaceuticals Holdings (RVPH)

April 5, 2025 | markets.businessinsider.com

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

March 31, 2025 | markets.businessinsider.com

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

March 30, 2025 | globenewswire.com

Why Reviva Pharmaceuticals Holdings, Inc.’s (RVPH) Stock Is Down 10.61%

March 7, 2025 | aaii.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

PMCB, RVPH, OSTX, and IRD Company Descriptions

Opus Genetics NASDAQ:IRD

$1.11 +0.05 (+4.72%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$1.10 -0.01 (-0.90%)

As of 04:38 AM Eastern

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

OS Therapies NYSE:OSTX

$1.66 +0.04 (+2.47%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$1.66 0.00 (-0.30%)

As of 04:33 AM Eastern

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

Nuvilex NASDAQ:PMCB

$1.11 +0.01 (+0.91%)

As of 07/9/2025 03:59 PM Eastern

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Reviva Pharmaceuticals NASDAQ:RVPH

$0.39 +0.01 (+3.53%)

Closing price 07/9/2025 04:00 PM Eastern

Extended Trading

$0.40 +0.01 (+1.82%)

As of 05:10 AM Eastern

Reviva Pharmaceuticals Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis. It is also developing RP1208 for the treatment of depression and obesity. Reviva Pharmaceuticals Holdings, Inc. was founded in 2018 and is headquartered in Cupertino, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time